Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (formerly NASDAQ: LUMO) has communicated that it is a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, with particular emphasis on Pediatric Growth Hormone Deficiency (PGHD). News about Lumos Pharma has frequently centered on the development of its lead candidate, LUM-201, an oral growth hormone secretagogue, and on key corporate milestones.
Company press releases describe a series of clinical updates from the Phase 2 OraGrowtH210 and OraGrowtH212 trials, where LUM-201 is being evaluated in children with moderate PGHD. These updates have highlighted growth outcomes, biomarker changes in IGF-1 and IGFBP-3, and detailed analyses of pulsatile growth hormone secretion patterns under LUM-201 treatment. Lumos Pharma has also reported presentations of these data at major endocrinology and pediatric endocrine conferences in regions including Europe, Latin America, and the Asia-Pacific.
In addition to clinical data, Lumos Pharma’s news flow has included information about regulatory interactions, such as its End of Phase 2 Meeting with the U.S. Food and Drug Administration regarding a potential placebo-controlled Phase 3 trial of LUM-201 in moderate PGHD. Financial updates, including quarterly results and cash position discussions, have also been part of the company’s public communications during its time as a listed entity.
A significant corporate development reported in the news is the successful completion of a tender offer and merger with Double Point Ventures LLC, after which Lumos Pharma’s common stock ceased trading on NASDAQ and the company began operating as a standalone business of Double Point Ventures. For readers reviewing the LUMO news archive, these items collectively provide historical context on Lumos Pharma’s clinical progress, regulatory discussions, financial reporting, and transition from a public company to a privately held business.
Lumos Pharma (NASDAQ:LUMO) presented additional data from its OraGrowtH212 trial at the 2023 International Meeting of Pediatric Endocrinology. The oral presentation highlighted a dose-dependent increase in growth hormone pulsatility and a correlation with heightened growth velocity, with data suggesting a durable response over 12 months. The OraGrowtH210 trial interim analysis indicated an annualized height velocity of 8.6 cm/year at 1.6 mg/kg/day. Both trials are now fully enrolled, with top-line results expected in Q4 2023, reinforcing optimism for LUM-201 as an oral treatment for Pediatric Growth Hormone Deficiency.
Lumos Pharma, Inc. announced the completion of patient enrollment in its Phase 2 OraGrowtH210 and OraGrowtH212 Trials, studying the oral therapeutic LUM-201 for idiopathic pediatric growth hormone deficiency (PGHD). Primary outcome data is expected in Q4 2023. The company reported a net loss of $31.1 million for 2022, slightly higher than the prior year. R&D expenses rose to $17.9 million due to clinical trial costs, while G&A expenses increased to $15.7 million, driven by royalty and travel expenses. Lumos ended 2022 with $67.4 million in cash, projected to last until Q3 2024, while preparing for a pivotal Phase 3 trial for LUM-201.
Lumos Pharma (NASDAQ:LUMO) announced the full enrollment of its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials for LUM-201, targeting Pediatric Growth Hormone Deficiency (PGHD). A total of 82 subjects are involved in the OraGrowtH210 trial, while 22 subjects are part of the OraGrowtH212 trial, which focuses on pharmacokinetic and pharmacodynamic effects. Primary outcome data is expected in Q4 2023. Interim results from the OraGrowtH210 trial showed a mean annualized height velocity of 8.6 cm/year, consistent with expectations. If LUM-201 receives FDA approval, it could be the first oral treatment for PGHD.
Lumos Pharma, Inc. (NASDAQ:LUMO) will report its full year 2022 financial results on March 1, 2023, after market close. A conference call will follow at 4:30 PM ET to discuss these results and updates on clinical and corporate activities. The company is advancing its oral therapeutic candidate, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. LUM-201 aims to provide an alternative to injections, having received Orphan Drug Designation in both the US and EU. Investors can access the conference call via a registration link or the Lumos Pharma website.
Lumos Pharma (NASDAQ:LUMO), a biopharmaceutical company, will participate in the 12th Annual LifeSci Partners Corporate Access Event in San Francisco from January 9-11, 2023. The company is advancing its oral therapeutic candidate, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. In-person one-on-one meetings with investors will be held on January 10th and 11th. LUM-201 has received Orphan Drug Designation in the US and EU, offering a new oral treatment alternative for PGHD patients.
Lumos Pharma hosted two key opinion leaders to discuss interim data from its Phase 2 trials of LUM-201 for moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD). The KOLs shared insights on the promising oral treatment option that has the potential to improve patient compliance compared to injectable therapies. Interim results indicated an annualized growth of 8.6 cm/year at 6 months, aligning with expected outcomes. The safety and tolerability of LUM-201 appear comparable to existing treatments. This novel approach could expand treatment options for patients previously deterred by injections.
Lumos Pharma (NASDAQ:LUMO) will host a KOL webinar on December 6, 2022, discussing interim data from its Phase 2 clinical trials, OraGrowtH210 and OraGrowtH212, focused on oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD). The webinar features leading experts in pediatric endocrinology, Dr. Andrew Dauber and Dr. Fernando Cassorla. LUM-201, an innovative oral therapy, received Orphan Drug Designation from the FDA and EU, promising an alternative to traditional injections for PGHD patients. A replay will be available on Lumos Pharma's website.
Lumos Pharma (NASDAQ:LUMO) announced its participation in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in Austin, Texas. The company will host a fireside chat on November 30 at 2:00 PM (EST) and will also hold one-on-one meetings on the same day. Lumos Pharma is focused on developing LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD), currently in Phase 2 trials. The presentation can be accessed through a webcast link available on their website.
Lumos Pharma announced positive interim results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials, demonstrating a mean annualized height velocity of 8.6 cm/yr for LUM-201 at a 1.6 mg/kg/day dose. The trial is approximately 80% enrolled, with full results expected in the second half of 2023. Financially, Lumos reported a cash position of $73.7 million, estimated to sustain operations into mid-2024. R&D expenses remained stable at $4.1 million, and the net loss for Q3 2022 was $7.3 million, showing improvement from $7.5 million lost in Q3 2021.
Lumos Pharma announced that interim results for LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD), were positive in two Phase 2 trials. The OraGrowtH210 Trial, with 80% enrollment, showed a mean annualized height velocity (AHV) of 8.6 cm at six months for the 1.6 mg/kg/day dose, aligning with historical expectations of 8.3 cm. These results validate the 1.6 mg/kg/day dose for a pivotal Phase 3 trial expected in 2H 2023. No safety concerns were reported, supporting the drug's continued development.